Targeting cancer with a lupus autoantibody

Science Translational Medicine

Volumn 4, Issue 157, 2012, Pages

  Hansen, James E ^a,b   Chan, Grace ^c   Liu, Yanfeng ^a   Hegan, Denise C ^a   Dalal, Shibani ^a   Dray, Eloise ^a,g   Kwon, Youngho ^a   Xu, Yuanyuan ^a   Xu, Xiaohua ^a   Peterson Roth, Elizabeth ^a   Geiger, Erik ^a   Liu, Yilun ^d   Gera, Joseph ^c,e   Sweasy, Joann B ^a,b,f   Sung, Patrick ^a,b   Rockwell, Sara ^a,b   Nishimura, Robert N ^c,e   Weisbart, Richard H ^c   Glazer, Peter M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA; DNA ANTIBODY; DOUBLE STRANDED DNA; DOXORUBICIN; LUPUS AUTOANTIBODY; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; LOW DRUG DOSE; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR CELL CULTURE; TUMOR XENOGRAFT;

ANIMALS; AUTOANTIBODIES; BRAIN NEOPLASMS; BRCA2 PROTEIN; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DNA, SINGLE-STRANDED; FEMALE; GLIOMA; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, NUDE; PROTEIN BINDING; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868020747     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004385     Document Type: Article

References (32)

1. D. Alarcón-Segovia, Antinuclear antibodies: To penetrate or not to penetrate, that was the question. Lupus 10, 315-318 (2001).
2. R. H. Weisbart, D. T. Noritake, A. L. Wong, G. Chan, A. Kacena, K. K. Colburn, A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J. Immunol. 144, 2653-2658 (1990).
3. D. J. Zack, M. Stempniak, A. L. Wong, C. Taylor, R. H. Weisbart, Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J. Immunol. 157, 2082-2088 (1996).
4. S. Lisi, M. Sisto, D. D. Lofrumento, S. D'Amore, M. D'Amore, Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake. Clin. Exp. Med. 11, 1-10 (2011).
5. J. E. Hansen, C. M. Tse, G. Chan, E. R. Heinze, R. N. Nishimura, R. H. Weisbart, Intranuclear protein transduction through a nucleoside salvage pathway. J. Biol. Chem. 282, 20790-20793 (2007).
6. F. Spertini, A. Leimgruber, B. Morel, M. B. Khazaeli, K. Yamamoto, J. M. Dayer, R. H. Weisbart, M. L. Lee, Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J. Rheumatol. 26, 2602-2608 (1999).
7. J. E. Hansen, W. Sohn, C. Kim, S. S. Chang, N. C. Huang, D. G. Santos, G. Chan, R. H. Weisbart, R. N. Nishimura, Antibody-mediated Hsp70 protein therapy. Brain Res. 1088, 187-196 (2006).
8. X. Zhan, B. P. Ander, I. H. Liao, J. E. Hansen, C. Kim, D. Clements, R. H. Weisbart, R. N. Nishimura, F. R. Sharp, Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke 41, 538-543 (2010).
9. J. E. Hansen, L. K. Fischer, G. Chan, S. S. Chang, S. W. Baldwin, R. J. Aragon, J. J. Carter, M. Lilly, R. N. Nishimura, R. H. Weisbart, M. E. Reeves, Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 67, 1769-1774 (2007).
10. K. M. Tewey, T. C. Rowe, L. Yang, B. D. Halligan, L. F. Liu, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466-468 (1984).
11. M. A. Jordan, R. J. Toso, D. Thrower, L. Wilson, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U.S.A. 90, 9552-9556 (1993).
12. G. C. Stachelek, S. Dalal, K. A. Donigan, D. C. Hegan, J. B. Sweasy, P. M. Glazer, Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase b is accentuated by BRCA2 mutation. Cancer Res. 70, 409-417 (2010).
13. C. Arnaudeau, C. Lundin, T. Helleday, DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 307, 1235-1245 (2001).
14. X. Li, W. D. Heyer, Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18, 99-113 (2008).
15. P. Sung, Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. Science 265, 1241-1243 (1994).
16. A. J. Pierce, R. D. Johnson, L. H. Thompson, M. Jasin, XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638 (1999).
17. M. E. Moynahan, A. J. Pierce, M. Jasin, BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263-272 (2001).
18. H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin, T. Helleday, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
19. W. G. Kaelin Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
20. Z. Feng, S. P. Scott, W. Bussen, G. G. Sharma, G. Guo, T. K. Pandita, S. N. Powell, Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl. Acad. Sci. U.S.A. 108, 686-691 (2011).
21. W. Sakai, E. M. Swisher, C. Jacquemont, K. V. Chandramohan, F. J. Couch, S. P. Langdon, K. Wurz, J. Higgins, E. Villegas, T. Taniguchi, Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381-6386 (2009).
22. P. C. Fong, D. S. Boss, T. A. Yap, A. Tutt, P. Wu, M. Merqui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M. J. O'Connor, A. Ashworth, J. Carmichael, S. B. Kaye, J. H. Schellens, J. S. de Bono, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
23. S. Bernatsky, R. Ramsey-Goldman, W. D. Foulkes, C. Gordon, A. E. Clarke, Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: A meta-analysis. Br. J. Cancer 104, 1478-1481 (2011).
24. S. Bernatsky, R. Ramsey-Goldman, C. Gordon, A. E. Clarke, Prostate cancer in systemic lupus erythematosus. Int. J. Cancer 129, 2966-2969 (2011).
25. S. Bernatsky, D. F. Easton, A. Dunning, K. Michailidou, R. Ramsey-Goldman, C. Gordon, A. E. Clarke, W. Foulkes, Decreased breast cancer risk in systemic lupus erythematosus: The search for a genetic basis continues. Lupus 21, 896-899 (2012).
26. J. R. McConnell, A. D. Crockard, A. P. Cairns, A. L. Bell, Neutrophils from systemic lupus erythematosus patients demonstrate increased nuclear DNA damage. Clin. Exp. Rheumatol. 20, 653-660 (2002).
27. S. Rockwell, Y. Liu, H. A. Seow, K. Ishiguro, R. P. Baumann, P. G. Penketh, K. Shyam, O. M. Akintujoye, P. M. Glazer, A. C. Sartorelli, Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int. J. Radiat. Biol. 88, 277-285 (2012).
28. X. Xu, P. J. Rochette, E. A. Feyissa, T. V. Su, Y. Liu, MCM10 mediates RECQ4 association with MCM2-7 helicase complex during DNA replication. EMBO J. 28, 3005-3014 (2009).
29. P. Chi, S. Van Komen, M. G. Sehorn, S. Sigurdsson, P. Sung, Roles of ATP binding and ATP hydrolysis in human Rad51 recombinase function. DNA Repair 5, 381-391 (2006).
30. E. Dray, M. H. Dunlop, L. Kauppi, J. San Filippo, C. Wiese, M. S. Tsai, S. Begovic, D. Schild, M. Jasin, S. Keeney, P. Sung, Molecular basis for enhancement of the meiotic DMC1 recombinase by RAD51 associated protein 1 (RAD51AP1). Proc. Natl. Acad. Sci. U.S.A. 108, 3560-3565 (2011).
31. D. C. Hegan, Y. Lu, G. C. Stachelek, M. E. Crosby, R. S. Bindra, P. M. Glazer, Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci. U.S.A. 107, 2201-2206 (2010).
32. J. San Filippo, P. Chi, M. G. Sehorn, J. Etchin, L. Krejci, P. Sung, Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. J. Biol. Chem. 281, 11649-11657 (2006).